| Analysis | Metabolite Name | Measured Value | Units | Group | TIMEPOINT |
|---|---|---|---|---|---|
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.1127 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.1187 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.1268 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.1275 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.1396 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.1444 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.1461 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.1897 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.2003 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.2288 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.2324 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.2368 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.2443 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.2604 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.2607 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.2761 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.2950 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.3196 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.3199 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.3203 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.3576 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.3713 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.3779 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.3801 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.3821 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.4218 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.4278 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.4331 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.4415 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.4591 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.4618 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.4861 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.4878 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.5042 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.5102 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.5217 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.5247 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.5468 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.5528 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.5582 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.5720 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.5744 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.5867 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.5976 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.6084 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.6145 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.6184 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.6308 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.6316 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.6646 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.6717 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.6717 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.6764 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.6813 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.6886 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.6908 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.7013 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.7083 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.7151 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.7168 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.7186 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.7216 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.7309 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.7460 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.7555 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.7573 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.7802 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.7821 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.7903 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.7949 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.8017 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.8184 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.8218 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.8229 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.8248 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.8299 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.8359 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.8437 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.8530 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.8675 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.8729 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.8752 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.8791 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.8935 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.8945 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.9095 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.9205 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.9466 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.9483 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.9529 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.9530 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.9861 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 0.9944 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.0000 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.0038 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.0139 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.0281 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.0438 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.0573 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.0906 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.1232 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.1262 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.1400 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.1442 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.1555 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.1664 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.1694 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.1846 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.1888 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.1997 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.2084 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.2200 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.2303 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.2347 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.2368 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.2995 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.3128 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.3274 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.3502 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.3878 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.3974 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.4368 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.4478 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.4546 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.4645 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.4867 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.4929 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.5030 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.5157 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.5508 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.5510 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.5677 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.5989 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.6048 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.6135 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.6317 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.6555 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.6636 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.6771 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.6807 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.6878 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.7024 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.7352 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.7489 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.7601 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.8076 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.8239 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.8939 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.9065 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.9140 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 1.9522 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 2.0355 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 2.0854 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 2.1062 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 2.1299 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 2.1564 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 2.1696 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 2.1717 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 2.1994 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 2.2048 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 2.2549 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 2.2600 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 2.2691 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 2.2996 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 2.3363 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 2.4150 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 2.4465 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 2.5303 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 2.5901 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 2.7528 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 2.7694 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 2.8572 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 2.9822 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 3.0065 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 3.1686 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 3.1688 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 3.1984 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 3.3434 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 3.3988 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 4.0439 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 4.2978 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 4.3647 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 4.4758 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 6.0096 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 6.2890 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 6.3522 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | palmitoleate (16:1n7) | 6.9900 | scaled units | Low-Dose | -0.5HR |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|